Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia

Jonathan E. Brammer, Karen Ballen, Lubomir Sokol, Christiane Querfeld, Ryotaro Nakamura, Anjali Mishra, Eric M. McLaughlin, David Feith, Nazli Azimi, Thomas A. Waldmann, Yutaka Tagaya, Thomas Loughran

Blood (2023) 142 (15): 1271–1280.

https://doi.org/10.1182/blood.2022017643

Published: 2023

Includes: Supplemental data

Journal Articles

Co-Inhibition of IL-2, IL-9 and IL-15 By the Novel Immunomodulator, Bnz-1, Provides Clinical Efficacy in Patients with Refractory Cutaneous T Cell Lymphoma in a Phase 1/2 Clinical Trial

Christiane Querfeld, MDPhD, Basem M. William, MDMRCP, Lubomir Sokol, MD PhD, Oleg Akilov, MD, Brian Poligone, MD PhD, Jasmine Zain, MD, Yutaka Tagaya, MD PhD, Nazli Azimi, PhD PharmD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-143135

Published: 2020

Journal Articles

Blockade of IL-15 Utilizing Bnz-1, a Selective γ-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemia (T-LGLL): Results of a Phase I/II Multi-Center Clinical Trial

Jonathan E. Brammer, MD, Lubomir Sokol, MD PhD, Yutaka Tagaya, MD PhD, Kerry Rogers, Anjali Mishra, PhD, Thomas A. Waldmann, MD, Nazli Azimi, PhD PharmD, Paul Frohna, MD PhD PharmD, Anoshie Ratnayake, MD, Thomas P Loughran, Jr., MD, Karen Ballen, MD

Blood (2019) 134 (Supplement_1): 2835.

https://doi.org/10.1182/blood-2019-129291

Published: 2019

Journal Articles

Bnz-1, a Selective γ-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: Results of a Multicenter, Open-Label Phase 1 Trial

Christiane Querfeld, MD PhD, Basem M. William, MRCP,MD, Jonathan E. Brammer, MD, Lubomir Sokol, MD PhD, Yutaka Tagaya, MD PhD, Paul Frohna, MD PhD PharmD, Nazli Azimi, PhD PharmD, Jasmine M. Zain, MD

Blood (2019) 134 (Supplement_1): 1557.

https://doi.org/10.1182/blood-2019-129201

Published: 2019

Journal Articles

Blockade of IL-2 and IL-15 Gamma Chain Receptor Signaling Decreases Leukemic Cell Viability in T-Cell Large Granular Lymphocyte Leukemia and Adult T-Cell Leukemia

Tracy Tiffany Wang, BS, Jun Yang, MD, Yong Zhang, PhD, Meili Zhang, PhD, Kevin C Conlon, MD, Yutaka Tagaya, B.M., PhD, Thomas L Olson, PhD, David J Feith, PhD, Nazli Azimi, Pharm.D., PhD, Thomas A. Waldmann, MD, Thomas P Loughran, Jr., MD

Blood (2017) 130 (Supplement 1): 3585.

https://doi.org/10.1182/blood.V130.Suppl_1.3585.3585

Published: 2017

Journal Articles

Results from a First-in-Human Study with Bnz-1: A Novel Peptide Inhibitor of IL-2, IL-9 and IL-15 for the Treatment of T-Cell Malignancies That Safely and Selectively Decreases Regulatory T-Cells, Natural Killer Cells, and CD8 + Central Memory T-Cells

Paul Frohna, MD PhD PharmD, Yutaka Tagaya, MD PhD, Anoshie Ratnayake, MD, Nick Doerr, PhD, Asjad Basheer, PhD, Laith Al-Mawsawi, Woo Jae Kim, PhD, Juan Zapata, PhD, Xisorong Wu, BS, Nazli Azimi, PhD PharmD

Blood (2017) 130 (Supplement 1): 695.

https://doi.org/10.1182/blood.V130.Suppl_1.695.695

Published: 2017

Journal Articles

Development of an IL-15–autocrine CD8 T-cell leukemia in IL-15–transgenic mice requires the cis expression of IL-15Rα

Noriko Sato, Helen Sabzevari, Song Fu, Wei Ju, Michael N. Petrus, Richard N. Bamford, Thomas A. Waldmann, Yutaka Tagaya

Blood (2011) 117 (15): 4032–4040.

https://doi.org/10.1182/blood-2010-09-307504

Published: 2011

Includes: Supplemental data

Journal Articles

CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP

Wei Ju, Meili Zhang, Jian-kang Jiang, Craig J. Thomas, Unsong Oh, Bonita R. Bryant, Jing Chen, Noriko Sato, Yutaka Tagaya, John C. Morris, John E. Janik, Steven Jacobson, Thomas A. Waldmann

Blood (2011) 117 (6): 1938–1946.

https://doi.org/10.1182/blood-2010-09-305425

Published: 2011

Includes: Supplemental data

Journal Articles

Acquisition of antigen presentasome (APS), an MHC/costimulatory complex, is a checkpoint of memory T-cell homeostasis

Sven Mostböck, Marta Catalfamo, Yutaka Tagaya, Jeffrey Schlom, Helen Sabzevari

Blood (2006) 109 (6): 2488–2495.

https://doi.org/10.1182/blood-2006-09-047290

Published: 2006

Journal Articles

Time to restore individual rights for IL-2 and IL-15?

Yutaka Tagaya

Blood (2006) 108 (2): 409–410.

https://doi.org/10.1182/blood-2006-05-019463

Published: 2006

Journal Articles

Physiological relevance of antigen presentasome (APS), an acquired MHC/costimulatory complex, in the sustained activation of CD4 + T cells in the absence of APCs

Jun Zhou, Yutaka Tagaya, Roshanak Tolouei-Semnani, Jeffrey Schlom, Helen Sabzevari

Blood (2005) 105 (8): 3238–3246.

https://doi.org/10.1182/blood-2004-08-3236

Published: 2005

Includes: Supplemental data

Journal Articles

Role of trans -cellular IL-15 presentation in the activation of NK cell–mediated killing, which leads to enhanced tumor immunosurveillance

Hisataka Kobayashi, Sigrid Dubois, Noriko Sato, Helen Sabzevari, Yoshio Sakai, Thomas A. Waldmann, Yutaka Tagaya

Blood (2005) 105 (2): 721–727.

https://doi.org/10.1182/blood-2003-12-4187

Published: 2005

Journal Articles

Memory depending on an intimate relationship

Yutaka Tagaya

Blood (2004) 103 (3): 755–756.

https://doi.org/10.1182/blood-2003-11-3843

Published: 2004

NARROW

Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia

Co-Inhibition of IL-2, IL-9 and IL-15 By the Novel Immunomodulator, Bnz-1, Provides Clinical Efficacy in Patients with Refractory Cutaneous T Cell Lymphoma in a Phase 1/2 Clinical Trial

Blockade of IL-15 Utilizing Bnz-1, a Selective γ-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemia (T-LGLL): Results of a Phase I/II Multi-Center Clinical Trial

Bnz-1, a Selective γ-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: Results of a Multicenter, Open-Label Phase 1 Trial

Blockade of IL-2 and IL-15 Gamma Chain Receptor Signaling Decreases Leukemic Cell Viability in T-Cell Large Granular Lymphocyte Leukemia and Adult T-Cell Leukemia

Results from a First-in-Human Study with Bnz-1: A Novel Peptide Inhibitor of IL-2, IL-9 and IL-15 for the Treatment of T-Cell Malignancies That Safely and Selectively Decreases Regulatory T-Cells, Natural Killer Cells, and CD8 + Central Memory T-Cells

Development of an IL-15–autocrine CD8 T-cell leukemia in IL-15–transgenic mice requires the cis expression of IL-15Rα

CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP

Acquisition of antigen presentasome (APS), an MHC/costimulatory complex, is a checkpoint of memory T-cell homeostasis

Time to restore individual rights for IL-2 and IL-15?

Physiological relevance of antigen presentasome (APS), an acquired MHC/costimulatory complex, in the sustained activation of CD4 + T cells in the absence of APCs

Role of trans -cellular IL-15 presentation in the activation of NK cell–mediated killing, which leads to enhanced tumor immunosurveillance

Memory depending on an intimate relationship

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only